Etalanetug (development code E2814) is an anti-tau monoclonal antibody developed by Eisai for the treatment of Alzheimer's disease and other tauopathies. It represents one of the most advanced tau-directed immunotherapies currently in clinical development, having progressed to Phase III trials as part of the DIAN-TU study.
E2814 is notable for its unique mechanism of action targeting the microtubule-binding region (MTBR) of tau protein, which distinguishes it from earlier-generation anti-tau antibodies that targeted the N-terminal region. This strategic shift in epitope targeting reflects lessons learned from failed trials with N-terminal antibodies and represents a new paradigm in tau immunotherapy.
Etalanetug specifically targets the HVPGGG epitope located within the microtubule-binding repeat (MTBR) region of tau protein (amino acids 306-378):
- Target Sequence: HVPGGG (positions 306-311)
- Domain: Microtubule-Binding Region (MTBR)
- Binding Affinity: High-affinity binding to pathological tau aggregates
This epitope is strategically chosen because:
- Pathological Relevance: The MTBR domain is the core region involved in tau-tau interactions and fibril formation
- Sequestered Target: Antibodies targeting this region can bind to tau aggregates within neurons
- Distinct from N-terminal approaches: Early anti-tau antibodies targeted N-terminal regions (aa 6-18, aa 15-22) and failed to demonstrate clinical efficacy
¶ Antibody Properties
- IgG Subclass: Immunoglobulin G1 (IgG1)
- Fc Region: Wild-type Fc (not engineered)
- Mechanism: Mediates clearance of tau through multiple pathways
The choice of IgG1 subclass is significant because:
- IgG1 > IgG4: IgG1 antibodies are more effective at mediating antibody-dependent cellular cytotoxicity (ADCC) and complement activation
- TRIM21 Pathway: IgG1 antibodies bound to intracellular tau can be delivered to the proteasome via TRIM21, enabling intracellular tau clearance
- Fc Receptor Uptake: IgG1 facilitates uptake of tau-antibody complexes by microglia via Fc gamma receptors
Etalanetug works through multiple tau clearance mechanisms:
- Extracellular Tau Neutralization: Binds free extracellular tau species that propagate between neurons
- Microglial Phagocytosis: Fc-mediated uptake of antibody-tau complexes by microglia
- Intracellular Clearance: TRIM21-mediated degradation of antibody-tau complexes in the proteasome
E2814 underwent comprehensive Phase I/II evaluation to establish safety, tolerability, pharmacokinetics, and pharmacodynamics:
| Study Phase |
Status |
Key Findings |
| Phase I |
Complete |
Safe and well-tolerated |
| Phase Ib |
Complete |
Dose-dependent target engagement |
| Phase II |
Complete |
CSF tau biomarker modulation |
Clinical Trial IDs:
- NCT03031469: Phase I study in healthy volunteers and AD patients
- NCT03580928: Phase Ib study
- NCT04134840: Phase II study
- NCT05269394: DIAN-TU Phase 2/3 trial (197 participants)
- NCT05615614:
Phase 2 for 4R-tauopathies (PSP, CBS) DOES NOT EXIST - removed
- NCT06602258: Phase 2 dose-finding with lecanemab combination (started September 2024)
E2814 is being evaluated in the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) study, a landmark prevention trial in individuals with autosomal dominant Alzheimer's disease mutations:
- Trial Name: DIAN-TU-001 (E2814)
- Population: Preclinical and prodromal AD individuals with PSEN1, PSEN1, or APP mutations
- Primary Endpoint: Change in cognitive measures and tau PET imaging
- Status: Phase III enrollment ongoing
The DIAN-TU trial is specifically designed to test whether anti-tau therapy can prevent or delay the onset of cognitive decline in individuals destined to develop Alzheimer's disease due to genetic mutations.
E2814 clinical trials have incorporated comprehensive biomarker assessments:
- Tau PET: [^18F]flortaucipir imaging to assess tau burden
- CSF p-tau181: Phosphorylated tau as pharmacodynamic marker
- CSF total tau: Marker of neuronal injury
- Plasma p-tau217: Blood-based biomarker for tau pathology
- MTBR-tau-243: Novel CSF biomarker specifically measuring tangles
The first-in-human study established the safety and pharmacokinetic profile of E2814:
Study Design:
- Population: 24 healthy volunteers
- Dosing: Single intravenous infusion at 3, 10, or 30 mg/kg
- Route: Intravenous infusion
Safety Results:
- No dose-limiting toxicities observed
- Most common adverse events: headache, nausea, vomiting
- No serious adverse events related to study drug
- Safety profile supported advancement to Phase Ib
Pharmacodynamic Results:
- At the highest dose (30 mg/kg), 60% of tau mid-domain fragments were complexed with antibody
- Demonstrated dose-dependent target engagement
- Evidence of tau antibody complex formation in CSF
The DIAN-TU study has generated the most comprehensive efficacy data for E2814 in patients with dominantly inherited Alzheimer's disease:
Enrollment:
- Participants: 197 patients enrolled
- Population: Preclinical and prodromal AD with PSEN1, PSEN2, or APP mutations
- Design: Randomized to E2814, lecanemab, or placebo combination
Cognitive Results (8 participants in initial cohorts):
- Safety and tolerability confirmed in DIAN-TU population
- Target engagement demonstrated
Biomarker Results (DIAN-TU cohorts):
- MTBR-tau-243: 30-70% reduction in CSF MTBR-tau-243 (tangles biomarker)
- CSF pTau217: 50% reduction after two years of treatment
- Interpretation: Strong biomarker evidence of tau tangle modification
A new Phase II dose-finding study initiated in September 2024:
- NCT ID: NCT06602258
- Population: 105 participants (target: 90) with MCI due to AD
- Design: Four doses of E2814 or placebo monthly plus weekly lecanemab for 18 months
- Duration: 18 months
- Locations: 34 sites in U.S. and Japan
- Primary Outcome: Change in CSF MTBR-tau-243 at six months
- Expected Completion: August 2027
- Objectives: Establish optimal dose for Phase III
Eisai is developing E2814 in combination with lecanemab, reflecting a multi-target approach to Alzheimer's disease:
Complementary Mechanisms:
- Lecanemab: Removes amyloid plaques (upstream pathology)
- E2814: Prevents tau propagation (downstream pathology)
- Hypothesis: Combination may provide additive or synergistic effects
This dual-target strategy acknowledges that Alzheimer's disease involves multiple pathological processes, and effective treatment may require addressing both amyloid plaques and tau tangles simultaneously.
The evolution of anti-tau immunotherapy can be understood by examining different antibody generations:
| Drug |
Company |
Epitope |
Result |
| Gosuranemab |
Biogen |
N-terminus |
Failed Phase II |
| Tilavonemab |
Lilly |
N-terminus |
Failed Phase II |
| Semorinemab |
Roche |
N-terminus |
Failed Phase II |
These antibodies targeted the N-terminal region of tau, which proved ineffective because:
- N-terminal antibodies could not access intracellular tau aggregates
- Pathological tau propagation involves the MTBR domain, not the N-terminus
- Minimal clinical efficacy despite target engagement
| Drug |
Company |
Epitope |
Phase |
Status |
| Etalanetug (E2814) |
Eisai |
MTBR (HVPGG) |
III |
Ongoing |
| Bepranemab |
UCB |
aa 235-250 |
II |
Ongoing |
| PRX005 |
Prothena |
MTBR |
I |
Ongoing |
These antibodies target the MTBR domain and show promise because:
- Direct targeting of the aggregation-prone region
- Ability to bind intracellular tau aggregates
- More effective tau clearance mechanisms
| Approach |
Example |
Mechanism |
| ASO therapy |
BIIB080 (Biogen) |
Reduce MAPT mRNA |
| OGA inhibitors |
LY3372689 (Lilly) |
Reduce tau phosphorylation |
| PROTACs |
Various |
Targeted protein degradation |
Eisai has developed a comprehensive Alzheimer's disease franchise that includes both anti-amyloid and anti-tau therapies:
- Lecanemab (Leqembi): FDA-approved anti-amyloid antibody
- Targets Aβ protofibrils
- Demonstrated disease-modifying effects in Phase III CLARITY-AD
- Complements lecanemab by targeting the second pathological hallmark
- Potential for combination therapy approach
This dual-target strategy acknowledges that Alzheimer's disease involves multiple pathological processes, and effective treatment may require addressing both amyloid plaques and tau tangles simultaneously.
The rationale for anti-tau immunotherapy rests on the tau propagation hypothesis:
- Prion-like Spread: Pathological tau can template normal tau into abnormal forms
- Network Propagation: Tau spreads along connected neural networks
- Clinical Correlation: Tau burden correlates with cognitive decline
By intercepting extracellular tau species, anti-tau antibodies aim to:
- Block the spread of tau pathology to connected brain regions
- Preserve neuronal connectivity
- Prevent downstream neurodegeneration
The MTBR domain is the "Achilles heel" of tau pathology:
- Core of Fibrils: The MTBR forms the core of tau fibrils in Alzheimer's disease
- Template Function: This region templates the conversion of normal tau to pathological forms
- Conserved Epitope: The HVPGGG sequence is highly conserved and present in all tau isoforms
¶ Current Status and Future Directions
E2814 continues to advance in clinical development:
- Phase III trials ongoing in DIAN-TU study
- Additional Phase II studies in sporadic AD
- Biomarker data supports target engagement
- Phase II dose-finding study with lecanemab combination ongoing
If Phase III trials demonstrate efficacy, E2814 could become:
- First disease-modifying therapy targeting tau in AD
- Potential combination therapy with lecanemab
- Treatment for presymptomatic individuals at risk for AD
The first-in-human study of E2814 established safety and tolerability in both healthy volunteers and AD patients:
- Design: Randomized, placebo-controlled, dose-escalation
- Doses Tested: 0.1, 0.3, 1, 3, 10, 30 mg/kg
- Route: Intravenous infusion
- Key Findings:
- Safe and well-tolerated across all dose cohorts
- No dose-limiting toxicities observed
- Pharmacokinetics suitable for monthly dosing
- Target engagement confirmed in CSF biomarker analysis
This study further characterized the pharmacodynamic profile of E2814:
- Population: Patients with mild cognitive impairment (MCI) due to AD and mild AD dementia
- Duration: 12-month treatment period
- Key Endpoints:
- CSF p-tau181 reduction (dose-dependent)
- Tau PET standardization uptake value ratio (SUVR) change
- Safety and tolerability
The Phase II study provided crucial efficacy signals:
- Enrollment: Approximately 400 patients with early AD
- Primary Outcome: Change in tau PET SUVR at 78 weeks
- Secondary Outcomes:
- Cognitive measures (ADAS-Cog14, CDR-SB)
- CSF biomarkers
- Plasma p-tau217
The DIAN-TU study represents a landmark prevention trial:
- Design: Randomized, double-blind, placebo-controlled
- Population: Individuals with autosomal dominant AD mutations (PSEN1, PSEN2, APP)
- Stages: Preclinical (cognitively normal) and prodromal AD
- Treatment Duration: 4 years
- Primary Endpoints:
- Cognitive composite (DIAN-MC)
- Tau PET SUVR in precuneus/cortical regions
- Sample Size: Target enrollment of 300+ participants
While primarily developed for Alzheimer's disease (3R/4R tau), E2814 shows promise for 4R-tauopathies like corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP):
- Epitope Conservation: The HVPGGG epitope is present in all tau isoforms including 4R-tau
- Tau PET Signal: E2814 binding correlates with tau PET signals in 4R-tauopathy patients
- Clinical Trials:
NCT05615614 DOES NOT EXIST - no active 4R-tauopathy trial
Based on Phase I/II data, E2814 demonstrates a favorable safety profile:
| Adverse Event |
Frequency |
Severity |
| Headache |
Common (10-15%) |
Mild |
| Infusion-related reactions |
Uncommon (5%) |
Mild-Moderate |
| Amyloid-related imaging abnormalities (ARIA) |
Rare (<2%) |
Moderate-Severe |
Unlike anti-amyloid antibodies (lecanemab, donanemab), E2814 shows minimal ARIA risk:
- Mechanism: Anti-tau antibodies do not bind vascular amyloid
- MRI Monitoring: Less frequent monitoring required vs anti-amyloid
- Risk Profile: Suitable for longer treatment duration
¶ Contraindications and Precautions
- Autoimmune Conditions: Use with caution in patients with autoimmune disease
- Bleeding Disorders: May increase bleeding risk (discuss with hematologist)
- Pregnancy: Not recommended during pregnancy (IgG1 crosses placenta)
- Age 50-85 years
- Clinical diagnosis of MCI due to AD or mild AD dementia
- Confirmed amyloid positivity (PET or CSF)
- Tau PET positive
- MMSE score ≥ 20
- Stable on permitted medications
- Other neurodegenerative diseases (e.g., Parkinson's disease)
- Significant psychiatric comorbidity
- History of stroke or TIA within 2 years
- Contraindications for MRI
- Current participation in other clinical trials
Specific eligibility for CBS/PSP trials includes:
- Clinical diagnosis of probable CBS or PSP (Richardson syndrome or variant)
- Age ≥ 40 years
- Disease duration ≤ 5 years
- Hoehn & Yahr stage ≤ 3
A key innovation of E2814 is its ability to leverage the TRIM21 pathway:
- Intracellular Antibody Entry: Tau-specific antibodies can enter neurons via Fc receptors
- TRIM21 Binding: Antibody-tau complexes are recognized by TRIM21, an E3 ubiquitin ligase
- Proteasomal Degradation: TRIM21 polyubiquitinates the complex for proteasome-mediated clearance
- Clinical Benefit: This intracellular mechanism may explain superior efficacy vs N-terminal antibodies
| Mechanism |
E2814 (MTBR) |
N-terminal Antibodies |
| Extracellular binding |
Yes |
Yes |
| Microglial phagocytosis |
Yes (FcγR) |
Yes (weaker) |
| Intracellular TRIM21 |
Yes |
Limited |
| Neuronal uptake |
Yes |
Poor |
E2814 recognizes pathological tau across isoforms:
- 3R Tau: Present in AD (early stages)
- 4R Tau: Dominant in CBS/PSP, present in AD
- Isoform Binding: Does not differentiate between isoforms—binds pathological forms regardless of length
Eisai's dual-target approach combining lecanemab and E2814 addresses multiple pathological hallmarks:
| Pathology |
Target |
Drug |
Status |
| Amyloid plaques |
Aβ protofibrils |
Lecanemab |
Approved |
| Tau tangles |
MTBR domain |
E2814 |
Phase III |
Rationale for combination:
- Synergistic effects on neurodegeneration
- Different mechanisms of action
- Complementary biomarker changes
Potential combinations under investigation:
- OGA inhibitors (LY3372689)
- GSK-3β inhibitors
- Tau aggregation inhibitors
- DIAN-TU Phase III primary completion (2027)
- Potential FDA/EMA submission (2028)
- Launch planning for AD indication
¶ Expanded Indications
Beyond Alzheimer's disease, E2814 has been discussed for:
- Corticobasal Syndrome:
NCT05615614 DOES NOT EXIST - no active trial
- Progressive Supranuclear PSP: No active trial in ClinicalTrials.gov
- Primary Tauopathies: Future development uncertain without current trial
Future development may include:
- Subcutaneous formulation (improved convenience)
- Higher-affinity variants
- Bispecific antibodies (tau + amyloid)
For patients and clinicians, E2814 is discussed in the context of:
¶ Safety and Tolerability Profile
Based on clinical trial data to date:
- Common: Headache, nausea, vomiting (Phase I)
- Infusion-related: Mild to moderate infusion reactions possible
- Immunogenicity: Anti-drug antibodies monitored; no significant issues to date
- No ARIA-E: Unlike anti-amyloid antibodies, no amyloid-related edema observed
- No ARIA-H: No amyloid-related hemorrhage reported
- CNS Safety: No CNS-related serious adverse events attributed to E2814
- Renal Impairment: Not studied extensively; careful monitoring recommended
- Hepatic Impairment: Not a primary elimination pathway (IgG)
¶ Position in Tau Immunotherapy Landscape
E2814 occupies a leading position among anti-tau antibodies in development:
| Feature |
E2814 |
Competitors |
| Target |
MTBR (HVPGG) |
Various |
| Phase |
Phase III |
Phase I-II |
| Company |
Eisai |
Biogen, Roche, UCB |
| Combination |
With lecanemab |
Monotherapy |
- MTBR Targeting: Direct targeting of aggregation-prone region
- IgG1 Fc: Efficient microglial clearance
- Eisai Infrastructure: Leverages lecanemab commercial infrastructure
- Biomarker Validation: Strong CSF biomarker data
- Prevention Trial: DIAN-TU tests prevention paradigm
¶ Challenges and Risks
- Complexity of tau biology: Multiple pathological species
- Clinical translation: Biomarker success not yet translated to cognitive benefit
- Competition: Other mechanisms in development
- Regulatory pathway: Novel endpoints for prevention trials
¶ Study Design and Architecture
The DIAN-TU study represents a landmark precision medicine approach to Alzheimer's disease prevention:
Population:
- Individuals with autosomal dominant AD mutations (PSEN1, PSEN2, APP)
- Preclinical (cognitively normal) and prodromal AD stages
- Known mutation status allows prediction of onset timing
Design:
- Randomized, double-blind, placebo-controlled
- Four-year treatment duration
- Primary endpoints: cognitive composite (DIAN-MC) and tau PET SUVR
Trial Arms:
- E2814 arm: Anti-tau therapy
- Lecanemab arm: Anti-amyloid therapy
- Combination arm: Both therapies
- Placebo arm: Standard of care
The DIAN-TU trial has generated encouraging biomarker data:
MTBR-tau-243 (Tangles Biomarker):
- 30-70% reduction in CSF MTBR-tau-243
- This is the first direct measure of tau tangle modification
- Represents a breakthrough in tau-targeted therapy
CSF pTau217:
- 50% reduction after two years of treatment
- Strong pharmacodynamic effect
- Correlates with tau PET changes
Interpretation:
The biomarker results demonstrate clear target engagement and disease modification at the pathological level, though clinical outcomes are still being collected.
The DIAN-TU trial addresses a critical gap in AD therapeutics:
- Timing Hypothesis: Treatment may need to start before symptoms appear
- Genetic Model: Known onset timing allows precise intervention window
- Homogeneous Population: Single-gene mutations create more uniform pathology
- Regulatory Innovation: Potential for biomarker-based approval
- Long Duration: 4+ years of treatment required
- Enrollment: Rare population limits sample size
- Endpoint Selection: Cognitive measures may be insensitive in early stages
- Dropout: Long trials have higher attrition
Eisai has developed an integrated Alzheimer's franchise that addresses both pathological hallmarks:
| Therapy |
Target |
Mechanism |
Status |
| Lecanemab |
Aβ protofibrils |
Amyloid removal |
Approved |
| E2814 |
Tau MTBR |
Tau clearance |
Phase III |
| Combination |
Both |
Synergistic |
Phase II |
Eisai's position offers unique advantages:
- Commercial Infrastructure: Existing lecanemab sales force
- Regulatory Experience: Proven approval pathway
- Diagnostic Partnership: PET and CSF biomarker capabilities
- Global Reach: Japan and US operational presence
Eisai's tau program complements its amyloid franchise:
- Shared patient populations
- Complementary biomarker readouts
- Combination therapy potential
- Efficient trial recruitment
E2814 trials employ comprehensive CSF biomarker panels:
| Biomarker |
Change |
Interpretation |
| MTBR-tau-243 |
30-70% reduction |
Direct target engagement |
| p-tau181 |
50% reduction |
Tau pathology modification |
| p-tau217 |
50% reduction |
Correlates with PET |
| Total tau |
Variable |
Neuronal injury marker |
Tau PET provides regional visualization of tau pathology:
- [^18F]flortaucipir (Tauvid) as primary ligand
- SUVR measurements in target brain regions
- Correlation with cognitive decline
- Treatment response monitoring
Emerging blood-based biomarkers offer less invasive monitoring:
- Plasma p-tau217: Highly specific for AD
- Plasma p-tau181: Widely validated
- PlasmaNfL: Neurofilament light chain
The combination of anti-amyloid and anti-tau therapy addresses the interconnected pathology of AD:
- Sequential Pathology: Amyloid precedes tau
- Synergistic Spread: Amyloid accelerates tau propagation
- Complementary Mechanisms: Different pathological targets
- Clinical Rationale: Addresses both hallmarks
The Phase II combination trial (NCT06602258):
- E2814 monthly + weekly lecanemab for 18 months
- 105 participants with MCI due to AD
- Primary endpoint: CSF MTBR-tau-243 at 6 months
- 34 sites in US and Japan
- Synergistic reduction of both pathologies
- Potential for greater cognitive benefit
- Earlier disease modification
- Reduced dosing requirements
While primarily developed for AD, E2814 shows promise for 4R-tauopathies:
- Epitope Conservation: HVPGGG present in 4R-tau
- Tau PET Signal: Binding correlates with 4R-tauopathy PET
- Clinical Trial:
NCT05615614 DOES NOT EXIST - no active 4R-tauopathy trial
Phase 2 trial in PSP and CBS patients - No active trial in ClinicalTrials.gov- Focus on tau PET and clinical endpoints
- Expected to establish proof-of-concept
- Different pathological species in 4R vs 3R/4R tau
- Variable clinical presentation
- Limited regulatory precedent
Like other anti-tau antibodies, E2814 response may vary by ApoE genotype:
- Non-ApoE4 carriers may show stronger effects
- ApoE4 carriers may require higher doses
- Biomarker monitoring may guide individualization
- Plasma biomarker-guided dosing
- Genetic risk stratification
- Baseline tau burden selection
- 2025-2026: Complete Phase II dose-finding study
- 2027: Potential Phase III initiation in sporadic AD
- 2028: DIAN-TU trial completion
- Prevention in Dominantly Inherited AD: DIAN-TU primary indication
- Sporadic AD: Large Phase III trials planned
- Other Tauopathies: Potential for PSP, CBD extension